Home
About Us
Company Overview
Innovation and Leadership
Products
Discovery
Company Highlights
Company History
Our People
Senior Management
Our Reach
Awards and Recognition
Australian Industry Participation Purchasing Policy
Positions Vacant
Legal Disclaimer
Our Products
Aridol
Current clinical trials
Aridol Distributors
Bronchitol
Current clinical trials
Bronchitol Product Information
Bronchitol Distributors
Respiratory Diseases
Named Patient Program (Compassionate Use)
Scientific Publications
Patents
Investors
ASX Announcements
ASX 2012
ASX 2011
ASX 2010
ASX 2009
ASX 2008
ASX 2007
ASX 2006
ASX 2005
ASX 2004
ASX 2003
News
Quarterly Reports
Annual Reports
Investor Presentations
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Share Price
Shareholder Services
Join Our Mailing List
Contact Us
Events Calendar
Financial Summary
Analyst Coverage
Shareholders
Corporate Directory
Corporate Governance
SEC Filings
Pharmaxis ADRs
News
Media Releases
Media 2012
Media 2011
Media 2010
Media 2009
Media 2008
Media 2007
Media 2006
Media 2005
Media 2004
Media 2003
Quarterly Reports
Quarterly Reports 2012
Quarterly Reports 2011
Quarterly Reports 2010
Quarterly Reports 2009
Quarterly Reports 2008
Quarterly Reports 2007
Quarterly Reports 2006
Quarterly Reports 2005
Quarterly Reports 2004
Media Contact
News Feeds
New Product Pipeline
Clinical Trials
Scientific Publications
Investigator-Initiated Studies
Respiratory diseases
Patents
Contact Us
Health Professionals
Patients
Media 2010
Bronchitol EU Marketing Authorisation Update
Extended Benefit with Bronchitol in Second Phase III Cystic Fibrosis Trial
Pharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol
Bronchitol Recommended for Approval by Australian Advisory Committee
Phase II Trial of ASM8 in Asthma Commences
Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
Chairman's Address to Annual General Meeting
Pharmaxis Chief Executive Officer Resumes Office
Recording of Investor Conference Call - 14 October 2010
Conference Call Details - September 2010 Quarterly Report to Shareholders
US Food and Drug Administration Approves Aridol
Agreement for European Marketing of Bronchitol
Recording of Investor Conference Call - 22 July 2010
Conference Call Details - Quarterly Report to Shareholders and Investor Conference Call
Update on Pharmaxis CEO
Archived News
Pharmaxis
Home
Media 2010
Chairman's Address to Annual General Meeting
20.10.2010 - Chairman's Address to Annual General Meeting
Chairman's Address to the 2010 Annual General Meeting held on 20 October 2010
Download Address
Back to Latest News